



XU, Shengao (Shaun)

Partner

Tel: +86 21 2208 6001
Fax: +86 21 5298 5492
E-mail: xushengao@junhe.com

Practice Areas:

Capital Market
Corporate and M&A
Private Equity/Venture Capital

Professional Experience

Mr. Shengao (Shaun) Xu joined JunHe in 2015 and specializes in capital markets, corporate and M&A and PE/VC matters. He has advised clients on the onshore and offshore offering and listing of securities, listed company's follow-on offerings, M&A and going-private transactions and listing structure's restructurings for onshore or offshore IPOs. He has represented companies in their PE/VC investments and offshore corporate bonds offerings. Prior to joining JunHe Mr. XU worked at a major US law firm's New York office and was responsible for handling China-related legal matters.

Mr. Xu has extensive experience in a broad range of industries, such as life science and healthcare, high-end intelligent household appliances, TMT, new energy, consumer retail (including e-commerce platforms), logistics, supply chains and semiconductors. He has represented and assisted various enterprise to complete a series of high-profile transactions.

Recent representative transactions include:

(1) Capital Markets

Mr. Xu assisted more than 10 companies in the IPO and listing on the onshore and offshore stock exchange, such as Zelgen Biopharmaceuticals (688266.SH), BeiGene (NASDAQ: BGNE, 06160.HK, 688235.SH), Hnova Biopharmaceuticals (688302.SH), MicroPort Medbot (2252.HK), Viva Biotech (1873.HK), Dingdong (NYSE: DDL), Amlogic (688099.SH), Ecovacs Robotics (603486.SH), ZTO Express (NYSE: ZTO), YTO Express (600233.SH), among which, BeiGene's IPO and listing on the STAR Market of Shanghai Stock Exchange was awarded as "ALB Hong Kong Law Awards" by the "Asian Legal Business" and "China Business Law Deals of the Year" by the "China Business Law Journal"; besides, Mr. XU was responsible for various follow-on offering and private placement equity transaction of domestic or overseas listed companies, including Zelgen Biopharmaceuticals (688266.SH), Viva Biotech (1873.HK), Ecovacs Robotics (603486.SH), BJ ENERGY INTL (686.HK)

(2) Merger and Acquisitions

Mr. XU possesses the ability to advise varieties of clients, such as private companies, listed companies, multinational corporate clients, etc., to complete the transactions. Mr. XU advised, such as LuPure Biotech, Viva Biotech (1873.HK), GDC, Rakuten (4755.T), etc. in their numerous complex M&A transactions; and advised the buyer consortiums in the going-private and delisting transaction of eLong (NASDAQ: LONG)

(3) PE/VC Transactions

Mr. XU possesses the ability to advise investor or company act as or company's counsel in various stages of PE investment under both domestic and red-chip transaction structure. Acting as investor's counsel, Mr. XU provided legal services for several well-known clients for numerous investment deals, such as CICC, CICC Capital, Tencent, NetEase, Temasek, Warburg Pincus, Hillhouse, GIC, CDH, H World, etc.; acting as company's counsel, Mr. XU provided legal services for several clients for the Pre-IPO onshore and offshore financing deals, including Hnova Biopharmaceuticals, LePure Biotech, Qyuns Therapeutics, Newsoara Biopharma, PharmaLegacy Laboratories, Cjia Apartment

Education

LLM., Fordham University (2014)
LLB., Zhejiang Sci-Tech University (2012)

Professional Associations

Admitted to practice law in the PRC
Admitted to practice law in the State of New York

Language Skills

English and Mandarin.